NOBILI, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.320
EU - Europa 7.618
AS - Asia 2.368
SA - Sud America 327
OC - Oceania 106
AF - Africa 51
Continente sconosciuto - Info sul continente non disponibili 2
Totale 19.792
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.255
PL - Polonia 2.739
RU - Federazione Russa 2.084
IT - Italia 826
HK - Hong Kong 787
SG - Singapore 719
IE - Irlanda 673
SE - Svezia 470
CN - Cina 393
BR - Brasile 294
DE - Germania 232
FI - Finlandia 153
IN - India 137
JO - Giordania 118
GB - Regno Unito 110
AU - Australia 104
FR - Francia 77
UA - Ucraina 77
TR - Turchia 55
VN - Vietnam 50
ID - Indonesia 43
CA - Canada 39
CH - Svizzera 36
NL - Olanda 34
CI - Costa d'Avorio 33
AT - Austria 29
BE - Belgio 25
ES - Italia 22
KR - Corea 19
MX - Messico 14
AR - Argentina 10
IQ - Iraq 8
BD - Bangladesh 6
MA - Marocco 6
CO - Colombia 5
GR - Grecia 5
IR - Iran 5
JP - Giappone 5
VE - Venezuela 5
AL - Albania 4
CZ - Repubblica Ceca 4
EC - Ecuador 4
LT - Lituania 4
PE - Perù 4
PK - Pakistan 4
SC - Seychelles 4
AE - Emirati Arabi Uniti 3
BB - Barbados 3
DK - Danimarca 3
EG - Egitto 3
IL - Israele 3
PY - Paraguay 3
BT - Bhutan 2
DO - Repubblica Dominicana 2
GE - Georgia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PR - Porto Rico 2
RO - Romania 2
TN - Tunisia 2
AM - Armenia 1
BG - Bulgaria 1
CL - Cile 1
CR - Costa Rica 1
EE - Estonia 1
EU - Europa 1
HU - Ungheria 1
JM - Giamaica 1
KE - Kenya 1
LV - Lettonia 1
MK - Macedonia 1
MN - Mongolia 1
MU - Mauritius 1
NI - Nicaragua 1
NP - Nepal 1
PH - Filippine 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TW - Taiwan 1
UY - Uruguay 1
UZ - Uzbekistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZA - Sudafrica 1
Totale 19.792
Salva come PNG Salva come JPEG
Città #
Warsaw 2.729
Santa Clara 2.402
Fairfield 884
Dublin 671
Chandler 669
Hong Kong 627
Ashburn 497
Woodbridge 433
Singapore 424
Cambridge 385
Seattle 377
Houston 367
Wilmington 317
Ann Arbor 224
Altamura 179
Princeton 173
Lawrence 168
Florence 151
Boston 126
Jacksonville 126
Beijing 125
Melbourne 102
Moscow 97
Mumbai 93
Boardman 86
Buffalo 83
Shanghai 71
Medford 68
Bremen 63
San Diego 60
Paris 49
Falls Church 47
New York 43
Jakarta 42
Kent 41
Munich 40
Izmir 37
Turku 36
Bern 34
Abidjan 33
Dong Ket 32
Norwalk 31
Rome 31
Dearborn 30
Hefei 28
Los Angeles 28
Vienna 26
Phoenix 25
Brussels 22
Hillsboro 22
London 21
São Paulo 21
Toronto 20
Bengaluru 18
The Dalles 18
West Jordan 16
Barcelona 15
Milan 15
Palermo 14
Andover 12
Belo Horizonte 11
Guangzhou 11
Helsinki 11
Pune 11
Redmond 11
Bari 10
Catania 10
Rio de Janeiro 10
Brasília 9
Montreal 9
San Francisco 9
Yubileyny 9
Bologna 8
Guadalajara 8
Seongnam 8
Auburn Hills 7
Frankfurt am Main 7
Laurel 7
Tappahannock 7
Athens 6
Council Bluffs 6
Kunming 6
Lappeenranta 6
Philadelphia 6
Seoul 6
Turin 6
Washington 6
Chicago 5
Fiesole 5
Frankfurt Am Main 5
Kilburn 5
Modena 5
Stockholm 5
Biella 4
Brooklyn 4
Cagliari 4
Duque de Caxias 4
Goiânia 4
Lastra a Signa 4
Livorno 4
Totale 13.903
Salva come PNG Salva come JPEG
Nome #
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 305
RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 303
In vitro assessment of antibody-conjugated gold nanorods for systemic injections 300
Proteomic Analysis of Ovarian Cancer Cell Responses to Cytotoxic Gold Compounds 295
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. 291
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 289
Emerging drugs in refractory colorectal cancer 285
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment 273
Natural compounds for cancer treatment and prevention 269
Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale - Farmaci inibitori di protein chinasi 267
Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 267
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c.) 263
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil 262
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. 262
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 257
Druggable Targets in Pancreatic Adenocarcinoma 253
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. 247
Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. 235
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic Acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. 231
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin 224
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 213
Selection and characterization of a human ovarian cancer cell line resistant to auranofin 210
Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issues. 192
Association of the HLA-G 3′UTR polymorphisms with colorectal cancer in Italy: a first insight 189
Analysis of Gene Expression Profiles Reveals Novel Correlations With the Clinical Course of Colorectal Cancer 181
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer 179
Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. 162
Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies 156
A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. 156
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 152
MOLECULAR CHARACTERIZATION OF ESTABLISHED HUMAN COLON CARCINOMA CELL LINES (HCT-8) MADE RESISTANT TO 5-FLUOROURACIL BY DIFFERENT SELECTION SCHEDULES 150
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 150
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 150
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors 150
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 149
Pharmacogenetics: Implementing personalized medicine 148
Cellular pharmacology of gemcitabine. 147
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 144
Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma 140
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. 138
Chronic inflammation in urothelial bladder cancer 135
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 133
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study 130
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 129
Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand. 129
Postoperative chemotherapy in resected gastric cancer: results of a single center experience. 128
Prognostic factors in primary and iterative surgery of colorectal liver metastases 124
Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study 124
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 123
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression 122
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer 120
THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY 118
Size dependent biological profiles of PEGylated gold nanorods 118
Pharmacological strategies for overcoming multidrug resistance. 117
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 115
Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience 115
Synthesis, Structural Characterization, Solution Behavior, and in Vitro Antiproliferative Properties of a Series of Gold Complexes with 2-(2'-Pyridyl)benzimidazole as Ligand: Comparisons of Gold(III) versus Gold(I) and Mononuclear versus Binuclear Derivatives 114
Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. 114
Erratum: The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways (Oncology Research 25:9 (1441-1451) DOI: 10.3727/096504017X14926854178616) 114
Pharmacological modulation of protein kinase C for overcoming drug resistance in colorectal cancer. Preliminary results of in vitro studies. 111
Role of ATP-binding cassette transporters in cancer initiation and progression 111
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 111
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients 110
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study 108
Preliminary results of a survey of the use of antimicrobial agents as prophylaxis in orthopedic surgery. 108
A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical development 106
Pharmacogenomic Markers of Clinical Efficacy in a Dose-Dense Therapy Regimen (R-CHOP14) in Diffuse Large B Cell Lymphoma 106
Does surgical prophylaxis with teicoplanin constitute a therapeutic advance? 104
Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials 104
PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients 104
In vitro study on the safety of near infrared laser therapy in its potential application as postmastectomy lymphedema treatment 104
Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma. 103
The genotype for DPYD risk variants in colorectal cancer patients and the related toxicity management costs in clinical practice. 103
Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers 102
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphysms in primary colorectal cancer patients. 102
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma 101
Immune checkpoint inhibitors in pre-treated gastric cancer patients: Results from a literature-based meta-analysis 101
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment 101
Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer 101
Biweekly (BW) chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT11), infusional 5-fluorouracil/folinic acid (FU/FA) in patients (pts) with metastatic colorectal cancer (MCRC) pretreated with CPT11- or OHP-based CHT 100
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. 99
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 97
Genomic and genetic alterations influence the progression of gastric cancer 97
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer 96
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis 95
Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer 95
An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC) 94
Sequence-dependent interactions between oxaliplatin and 5-fluorouracil in human colon carcinoma cell lines 93
Thymidylate Synthase (TS) mRNA expression and TS gene promoter polymorphism in primary colorectal cancer (CRC) patients (PTS) receiving post-operative fluorouracil (5-FU)-based chemotherapy (CT) 93
Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand? 93
Administering gemcitabine as fixed-dose-rate infusion in combination with cisplatin, potentially effective target plasma concentrations are achieved in patients with advanced non-small cell lung cancer 92
Analisi dell'espressione di geni coinvolti nella resistenza al 5-fluorouracile nel carcinoma colorettale 91
Mechanisms of methotrexate (MTX) resistance in human colon carcinoma cells DLD-1 90
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer. 90
The clinical role of PIK3CA mutations in colorectal cancer 89
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer 89
Adverse drug reactions in oncoLogy: intEnsive monitoring program on drug toXicity of biotechnological medicatioNs anD taRget therapies in Oncologic patientS - the ALEXANDROS observational study 88
Biweekly (BW) chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT11), infusional 5-fluorouracil/folinic acid (FU/FA) in patients (PTS) with metastatic colorectal cancer (MCRC) pretreated with CPT11- or OHP-based CHT. 88
Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge 88
Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer 87
Totale 15.001
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.600
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.600
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202061 0 0 0 0 0 0 0 0 0 0 0 61
2020/20211.826 140 184 70 208 120 196 115 132 186 255 91 129
2021/20221.089 28 116 62 47 30 69 40 101 65 49 153 329
2022/20233.103 276 533 119 279 219 560 372 183 379 15 71 97
2023/20241.225 50 116 193 37 91 142 99 266 30 78 64 59
2024/20257.548 312 829 501 1.152 2.076 960 149 375 432 207 323 232
Totale 20.073